LOS ANGELES, March 17, 2025 /PRNewswire/ — The DJS Law Group reminds investors of a class action lawsuit against ModivCare Inc. (“ModivCare” or “the Company”) (NASDAQ: MODV) for violations of the federal securities laws. Shareholders who purchased the Company’s securities between…
Category: Uncategorized
REDMOND, Wash., March 17, 2025 /PRNewswire/ — Microsoft Corp. has received notice of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (TRC) dated Feb.21, 2025, to purchase up to 300,000 shares of Microsoft’s common stock at a price of $391.00 per share in cash….
-Represents Approximately 21.5% Payout Ratio of Net Income for FY 2024- -Marks seventh consecutive year of dividend declaration- -Revised Dividend Policy of between 20% to 30% of net income for 2025 onward- SHANGHAI, March 17, 2025 /PRNewswire/ — FinVolution Group (“FinVolution,” or the…
SHANGHAI, March 17, 2025 /PRNewswire/ — FinVolution Group (“FinVolution,” or the “Company”) (NYSE: FINV), a leading fintech platform in China, Indonesia and the Philippines, today announced that the board of directors of the Company (the “Board”) has authorized a new share repurchase…
LOS ANGELES, March 17, 2025 /PRNewswire/ — The DJS Law Group announces that it is investigating claims on behalf of investors of Ibotta, Inc. (“Ibotta” or “the Company”) (NYSE: IBTA) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the…
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV…
-Full Year 2024 Transaction Volume reached RMB206.2 billion, up 6.1% year-over-year- -Full Year 2024 International Transaction Volume exceeded RMB10.1 billion, up 27.8% year-over-year- -Full Year International Revenues reached RMB2.5 billion, up 18.5% year-over-year and representing 19.4%…
La combinaison TMB-365/TMB-380 démontre une suspension virale sans nécessité d’épreuve de sensibilité TaiMed Biologics va revoir la gestion des traitement contre le VIH et recherche des collaborations stratégiques avec des partenaires pharmaceutiques mondiaux pour commercialiser sa…
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV…
– TaiMed Biologics anuncia en la CROI 2025 los resultados de los últimos datos de fase 2a sobre la terapia de mantenimiento de acción prolongada contra el VIH La combinación TMB-365/TMB-380 demuestra la suspensión viral sin necesidad de pruebas de susceptibilidad TaiMed Biologics…